Utama › Tumor Neuroendokrin › California

Kajian klinikal Tumor Neuroendokrin di California

14 kajian untuk Tumor Neuroendokrin sedang mencari peserta di lokasi di California.

Bandar di California

Teks kajian rasmi (Bahasa Inggeris)

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Cedars-Sinai Medical Center, Beverly Hills
Norris Comprehensive Cancer Center, Los Angeles
Stanford Cancer Center, Palo Alto
dan 2 lagi

Mengambil pesertaFasa 2/3

Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06943755

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

UCSF Benioff Children's Hospital, San Francisco

Mengambil pesertaFasa 1

24 Months – 18 Years · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06441331

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Hoag Memorial Hospital Presbyterian, Newport Beach

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07087054

Project: Every Child for Younger Patients With Cancer

Kaiser Permanente Downey Medical Center, Downey
City of Hope Comprehensive Cancer Center, Duarte
Loma Linda University Medical Center, Loma Linda
dan 15 lagi

Mengambil pesertaKajian pemerhatian

Sehingga umur 25 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT02402244

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Crinetics Study Site, Duarte
Crinetics Study Site, Newport Beach
Crinetics Study Site, Orange
dan 1 lagi

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT07129252

CapTemY90 for Grade 2/3 NET Liver Metastases

UC San Diego, La Jolla

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 4 Jun 2026 · NCT04339036

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

St Joseph Heritage Healthcare, Santa Rosa

Mengambil pesertaFasa 1/2

Umur 12 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT03093116

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Stanford University, Palo Alto

Mengambil pesertaFasa 1/2

Umur 20 hingga 99 · Semua jantina · Dikemas kini 20 Apr 2026 · NCT02174549

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Research Facility, Irvine

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 30 Mac 2026 · NCT05477576

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

City of Hope, Duarte
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Stanford Cancer Institute, Stanford

Mengambil pesertaFasa 1

Umur 18 hingga 75 · Semua jantina · Dikemas kini 17 Mac 2026 · NCT04119024

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

University of California, San Francisco, San Francisco

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT05746208

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Cedars-Sinai Medical Center, Los Angeles

Mengambil peserta

Umur 18 hingga 99 · Semua jantina · Dikemas kini 20 Feb 2026 · NCT04907643

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

University of Southern California, Los Angeles

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 11 Dis 2025 · NCT06943521

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Duarte
Massive Bio SYNERGY-AI site, Irvine
Massive Bio SYNERGY-AI site, La Jolla
dan 3 lagi

Mengambil pesertaKajian pemerhatian

Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.